Current Report Filing (8-k)
February 23 2021 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported): February
17, 2021
ZOMEDICA CORP.
|
(Exact name of registrant as specified in its charter)
|
Alberta, Canada
|
|
001-38298
|
|
N/A
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
100 Phoenix Drive, Suite 125, Ann Arbor, Michigan
|
|
48108
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (734)
369-2555
N/A
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Shares, without par value
|
ZOM
|
NYSE American
|
Item 8.01 Other Events.
Four executive officers and four directors have
adopted trading plans pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Plans”). The
Plans were entered into for a variety of reasons including long-term financial planning, retirement planning, and diversification
purposes.
Under Rule 10b5-1, directors, officers, and
other employees who may be exposed from time to time to material non-public information may adopt a pre-arranged plan or contract
at a time when they are not in possession of material non-public information for the sale of company securities under specified
conditions and at specified times. Using these 10b5-1 plans, individuals gradually can diversify their investment portfolios, spread
stock trades out over an extended period of time to reduce market impact, and avoid concerns about transactions occurring at a
time when they might possess material non-public information. A Rule 10b5-1 plan also may allow an insider to exercise, on specific
future dates, a stock option that may be nearing expiration, and simultaneously sell some or all of the shares underlying the option
to generate the cash needed to pay the exercise price of the option and related income tax obligations. The Plans cover a maximum
of 11,997,730 common shares; however, some, none or all of those common shares ultimately may be sold depending on the terms of
the individual Plans and the trading price of the Company’s common shares.
Transactions under the Plans will be reported
to the Securities and Exchange Commission in accordance with applicable securities laws, rules, and regulations. Zomedica Corp.
does not undertake to report Rule 10b5-1 plans that may be adopted by any officers or directors in the future, or to report any
modifications or termination of any publicly announced trading plan, except to the extent required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ZOMEDICA CORP.
|
|
|
|
|
|
|
Date: February 23, 2021
|
|
By: /s/ Ann Marie Cotter
|
|
|
Name: Ann Marie Cotter
|
|
|
Title: Chief Financial Officer
|
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Sep 2023 to Sep 2024